Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Type1_Research_Developments_6-2020
Gifts of Stock
The CMTA is strongly committed to client services and to funding research and finding a cure. Gifts to client services make the day-to-day function of the CMTA possible, enabling us…
What is CMT?
…Accelerate Research (STAR) in 2008, CMTA has been working with preeminent researchers, clinicians, patients and institutions in the global inherited neuropathy community to capitalize on breakthroughs in genetics. Unlike other…
Types of CMT
…because, by nerve conduction characteristics, it is neither demyelinating nor axonal – it is somewhere in between – it is intermediate. Learn more about how CMTA is accelerating research for…
Type1_Research_Developments
Invitae Announces Major Expansion of Its Neurology Test Offerings
…17 existing neurology panels based on new discoveries in genetics research. With this latest expansion of its test offerings, Invitae will be able to provide clinicians, patients, and payers with…
Translational Advances
The CMTA’s research is done in teams consisting of academic labs and clinical centers sponsored by the CMTA (STAR members), working together and with alliance partners in consortium team efforts….
Volunteer Spotlight: Amy Keller
…covered with the CMTA STARS Amy has sold to raise funds for CMT research. One fateful day, Amy recalls, she decided she was tired of feeling down about her diagnosis…
New Mobile App Simplifies Sign-Up for Patient Registry
A new mobile app developed by the Rare Diseases Clinical Research Network (RDCRN) makes it easier than ever for CMT patients to sign up for and navigate the network’s patient…
NJ/NYC Focus Group with Acceleron Pharma
The goal of Patients as Partners in Research is to advance the work of our Strategy to Accelerate Research (STAR) and enroll the patient community in the critical work of…